Biotech Values

[mcbio]

it's always been boom or bust, and starting to look much more like bust. Too bad, as they had one of the few potential drugs post Xtandi. Likely drug just isn't sufficiently potent.

Thanks Peter. It would be interesting to hear of others coming along also developing a drug against this target. Surely there are others to come with better potency.

As to whether the drug is doing anything, it would be nice to see individual PSA graphs. if prior to the drug the PSA levels were shooting up, then even a moderate decline might mean something.

Makes sense. If they don't have those graphs, presumably doesn't bode well as they should have every incentive to get the data out there in the best light.